Finch Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

finchtherapeutics.com

Founded Year

2014

Stage

IPO | IPO

Total Raised

$185.5M

Date of IPO

3/19/2021

Market Cap

0.10B

Stock Price

2.28

About Finch Therapeutics

Finch Therapeutics (NASDAQ: FNCH) feeds clinical studies of microbial interventions into its integrated machine-learning platform to identify the specific microbial agents that drive clinical responses. This human-first discovery enables Finch Therapeutics to develop these microbes as Microbiotics, a new class of orally administered biological drugs.

Finch Therapeutics Headquarter Location

200 Inner Belt Road Suite 400

Somerville, Massachusetts, 02143,

United States

617-229-6499

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Finch Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Finch Therapeutics in 1 CB Insights research brief, most recently on May 24, 2019.

Expert Collections containing Finch Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Finch Therapeutics is included in 4 Expert Collections, including Omics.

O

Omics

275 items

A

Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health

12,800 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

B

Biopharma Tech

838 items

Finch Therapeutics Patents

Finch Therapeutics has filed 3 patents.

The 3 most popular patent topics include:

  • Bacteriology
  • Digestive system
  • Bacterial plant pathogens and diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/9/2019

Bacteriology, Enterobacteriaceae, Sedatives, Digestive system, Bacterial plant pathogens and diseases

Application

Application Date

12/9/2019

Grant Date

Title

Related Topics

Bacteriology, Enterobacteriaceae, Sedatives, Digestive system, Bacterial plant pathogens and diseases

Status

Application

Latest Finch Therapeutics News

Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M

May 16, 2022

Finch Therapeutics press release (NASDAQ: FNCH ): Q1 GAAP EPS of -$0.52. Revenue of $0.35M. Shares +3.59%. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Finch Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Finch Therapeutics Rank

  • When was Finch Therapeutics founded?

    Finch Therapeutics was founded in 2014.

  • Where is Finch Therapeutics's headquarters?

    Finch Therapeutics's headquarters is located at 200 Inner Belt Road, Somerville.

  • What is Finch Therapeutics's latest funding round?

    Finch Therapeutics's latest funding round is IPO.

  • How much did Finch Therapeutics raise?

    Finch Therapeutics raised a total of $185.5M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.